ArticleScientific reports2025

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system.

Chufeng Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.